BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.

Alimera Sciences, Inc. announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3, 2019.

The so-called “heart-in-a-jar” will be created from human stem cells and designed to reproduce key phenotypic characteristics of heart failure.

If you run a team, you know the power of motivation. Yes, you likely hired people who are very self-motivated and want to succeed for their own satisfaction, but don’t discount what a little appreciation can do to boost someone up.

With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.

Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.

The company’s shares exploded 300% in after-hours trading yesterday at the news, giving the company a market value of $469.6 million.

The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.

As we begin the final month of 2019, the U.S. Food and Drug Administration has several PDUFA dates to approve drug applications.